U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07403968) titled 'A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease' on Feb. 04.
Brief Summary: Crohn's disease (CD) is a serious, long-term condition that can cause swelling (inflammation) and painful ulcers anywhere in the gut. The main aim of this study is to evaluate how safe zasocitinib is and how well it is tolerated by adults with CD.
The participants will be treated with zasocitinib for 3 months (12 weeks) and will need to undergo a test where a doctor uses a thin, flexible tube with a tiny camera to look inside the large bowel (colon) and the end of the small bowel (ileum); this test is called ileocolonoscopy.
During t...